Welcome to the e-CCO Library!

P636: Impact of anti-TNF treatment on extra-intestinal manifestations in patients with inflammatory bowel disease: real-world data in Germany
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

D. Bettenworth*1, W-J. Lee2, R. S. Clark2, S. Rath3, M. Yang4, A. Bensimon4, S. Vavricka5

Created: Friday, 22 February 2019, 9:41 AM
P636: Long-term outcome of anti-tumour necrosis factor treatment in inflammatory bowel disease: A real-life observational study at Østfold Central Hospital, Norway
Year: 2018
Source: ECCO '18 Vienna
Authors:

F. Lerang1*, E. Gunther2, M. Henriksen1, L.-P. Jelsness-Jørgensen1,3

Created: Thursday, 21 February 2019, 9:14 AM
P636: Real-world clinical effectiveness and safety of vedolizumab and ustekinumab in biologic-naïve patients with Crohn's disease: Results from the EVOLVE Expansion study
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Ferrante, M.(1)*;Christensen, B.(2,3);Bressler, B.(4);Brett, N.(5);Bassel, M.(5);Kamble, P.(6);Adsul, S.(6);Gianchetti, L.(7);Scharl, M.(8);
Created: Friday, 14 July 2023, 11:12 AM
P636: Reproducibility of the main prognostic factors for postoperative recurrence in a cohort of patients with Crohn's disease under anti-Tnf therapy
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Raimundo Fernandes S.*1, Correia L.1, Baldaia C.2, Moura Santos P.2, Rita Gonçalves A.2, Valente A.2, Velosa J.1

Created: Wednesday, 20 February 2019, 10:36 AM
P636: The natural history of COVID-19 in patients with IBD: A nationwide study by the Hellenic Society for the Study of IBD.
Year: 2021
Source: ECCO'21 Virtual
Authors: Bamias, G.(1);Kokkotis, G.(1);Christodoulou, D.(2);Delis, V.(3);Gatopoulou, A.(4);Giouleme, O.(5);Kalantzis, C.(6);Kapsoritakis, A.(7);Karatzas, P.(8);Karmiris, K.(9);Katsanos, K.(2);Kevrekidou, P.(10);Mathou, N.(11);Michalopoulos, G.(12);Michopoulos, S.(13);Papaconstantinou, I.(14);Polymeros, D.(15);Potamianos, S.(7);Poulopoulos, G.(1);Protopappas, A.(16);Soufleris, K.(10);Theodoropoulou, A.(9);Triantafillidis, J.K.(17);Triantafyllou, K.(15);Tsiolakidou, G.(18);Tsironi, E.(19);Tzouvala, M.(20);Viazis, N.(21);Zacharopoulou, E.(20);Zampeli, E.(13);Papatheodoridis, G.(8);Mantzaris, G.J.(21);
Created: Wednesday, 2 June 2021, 4:12 PM
P636: Work disability after 20 years with Inflammatory Bowel Disease - results from the IBSEN study
Year: 2022
Source: ECCO'22
Authors: Lund, C.(1,2);Kristensen, V.A.(1,3);Monstad, I.L.(3);Solberg, I.C.(1);Hovde, Ø.(4);Huppertz-Hauss, G.(5);Henriksen, M.(6);Høie, O.(7);Bernklev, T.(8);Jahnsen, J.(1,9);Moum, B.(1,2);Høivik, M.L.(1,2);
Created: Friday, 11 February 2022, 3:56 PM
P637 PERFUSE: A french non-interventional cohort study of infliximab-naive and transitioned patients receiving infliximab biosimilar SB2; An interim analysis
Year: 2020
Source:

ECCO'20 Vienna

Authors:

Y. Bouhnik1, B. Fautrel2, G. Desjeux3, U. Freudensprung4, A. Brigui5, J. Addison6

Created: Thursday, 30 January 2020, 10:12 AM
P637: Anti-infliximab antibody concentrations guide therapeutic decision-making in patients with Crohn's disease losing clinical response
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Dreesen E.*1, Van Stappen T.1, Ballet V.2, Tops S.1, Compernolle G.1, Van Assche G.2, Ferrante M.2, Vermeire S.2, Gils A.1

Created: Wednesday, 20 February 2019, 10:36 AM
P637: High faecal and serum tumour necrosis factor-α levels are associated with non-response to infliximab in patients with ulcerative colitis
Year: 2018
Source: ECCO '18 Vienna
Authors:

H. Meringer1,2,3*, N. Maharshak1,2,3, Y. Ron1,3, H. Yanai1,3,4, S. Cohen-Kedar1,2,3,4, I. Dotan1,2,3,4

Created: Thursday, 21 February 2019, 9:14 AM
P637: Incidence rate and clinical outcome of severe COVID-19 in Inflammatory Bowel Disease patients in a population-based setting
Year: 2021
Source: ECCO'21 Virtual
Authors: Rezazadeh Ardabili, A.(1,2);Creemers, R.H.(2,3);Jonkers, D.M.A.E.(1,2);Romberg-Camps, M.J.L.(3);Pierik, M.J.(1,2);van Bodegraven, A.A.(3);
Created: Wednesday, 2 June 2021, 4:12 PM
P637: MMP-2 and -8 degraded and citrullinated-vimentin (VICM) correlates to disease activity in inflammatory bowel diseases
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

L. Godskesen1, M. Lindholm2, J. Høg Mortensen2, A. Krag1, T. Manon-Jensen2, M. Karsdal2, J. Kjeldsen1

Created: Friday, 22 February 2019, 9:41 AM
P637: Risks of Development of COVID-19 among Patients with Inflammatory Bowel Disease
Year: 2022
Source: ECCO'22
Authors: Kappelman, M.(1);Zhang, X.(1);Lewis, J.(2);Melmed, G.(3);Siegel, C.(4);Cerciello, E.(5);Dobes, A.(5);Weaver, A.(5);Weisbein, L.(6);Long, M.(7);
Created: Friday, 11 February 2022, 3:56 PM
P637: Targeting mucosal healing: dose optimization of Vedolizumab in IBD patients with inadequate endoscopic response to standard dosing
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Dal Buono, A.(1)*;Gabbiadini, R.(1);Migliorisi, G.(1);Solitano, V.(1);Canziani, L.(2);Repici, A.(3,4);Armuzzi, A.(1,4);
Created: Friday, 14 July 2023, 11:12 AM
P638 Stenotic Crohn’s disease
Year: 2020
Source:

ECCO'20 Vienna

Authors:

W. El Ouardi, L. Nawal, B. Imane, B. Camelia, B. Mohamed, A. Fatima Zahra

Created: Thursday, 30 January 2020, 10:12 AM
P638: Abstract has been withdrawn.
Year: 2022
Source: ECCO'22
Created: Friday, 11 February 2022, 3:56 PM
P638: BMS-986165, an oral selective tyrosine kinase 2 (TYK2) inhibitor, does not affect the pharmacokinetics of methotrexate in healthy subjects
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

A. Chimalakonda*1, J. Jones III2, R. Dockens1, J. Throup1, S. Banerjee1, I. Girgis1

Created: Friday, 22 February 2019, 9:41 AM
P638: Changes in the management of IBD patients since the onset of COVID-19 pandemic. A path towards the implementation of telemedicine in Spain?
Year: 2021
Source: ECCO'21 Virtual
Authors: Del Hoyo Francisco, J.(1);Millán, M.(2);Garrido-Marín, A.(1);Nos, P.(1);Barreiro-de Acosta, M.(3);Bujanda, L.(4);de la Portilla, F.(5);Aguas, M.(1);
Created: Wednesday, 2 June 2021, 4:12 PM
P638: Effectiveness and safety of risankizumab induction therapy for 100 patients with Crohn's disease: a GETAID multicentre cohort study
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Fumery, M.(1)*;Defrance, A.(2);Roblin, X.(3);Altwegg, R.(4);Caron, B.(5);Hebuterne, X.(6);Carmen, S.(7);Meyer, A.(8);Nachury, M.(9);Laharie, D.(10);Nancey, S.(11);Le Berre, C.(12);Serrero, M.(13);Geyl, S.(14);Gilletta, C.(15);Ah Soune, P.(16);Duveau, N.(17);Uzza, M.(18);Abitbol, V.(19);Biron, A.(20);Tran Minh, M.L.(21);Paupard, T.(22);Vuitton, L.(23);Elgharabawy, Y.(2);Peyrin-biroulet, L.(5);
Created: Friday, 14 July 2023, 11:12 AM
P638: Nutritional status in paediatric Crohn’s disease patients: Does exclusive enteral nutrition help?
Year: 2018
Source: ECCO '18 Vienna
Authors:

C. Strisciuglio1*, E. Scarpato2, M.R. Serra2, F.P. Giugliano2, S. Cenni2, C. Mainolfi3, M. Martinelli2, E. Miele2

Created: Thursday, 21 February 2019, 9:14 AM
P638: Release of 5-aminosalicylic acid from mesalazine formulations: a novel dynamic dissolution model simulating gastrointestinal pH changes
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Demyanova E.1, Vakhitov T.1, Sitkin S.*1,2

Created: Wednesday, 20 February 2019, 10:36 AM